Journal of Bone Oncology Journal of Bone Oncology, Vol 13, Iss, Pp 123-135 (2018) Dipòsit Digital de la UB Universidad de Barcelona Coleman, R, Collinson, M, Gregory, W, Marshall, H, Bell, R, Dodwell, D, Keane, M, Gil, M, Barrett-lee, P, Ritchie, D, Bowman, A, Liversedge, V, De Boer, R, Passos-coelho, J, O'reilly, S, Bertelli, G, Joffe, J, Brown, J, Wilson, C, Tercero, J, Jean-mairet, J, Gomis, R & Cameron, D 2018, ' Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). ', Journal of Bone Oncology . https://doi.org/10.1016/j.jbo.2018.09.008
Rajendram, R, Taylor, P N, Wilson, V J, Harris, N, Morris, O C, Tomlinson, M, Yarrow, S, Garrott, H, Herbert, H M, Dick, A D, Cook, A, Gattamaneni, R, Jain, R, Olver, J, Hurel, S J, Bremner, F, Drummond, S R, Kemp, E, Ritchie, D M, Rumsey, N, Morris, D, Lane, C, Palaniappan, N, Li, C, Pell, J, Hills, R, Ezra, D G, Potts, M J, Jackson, S, Rose, G E, Plowman, N, Bunce, C, Uddin, J M, Lee, R W J & Dayan, C M 2018, ' Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED) : a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial ', Lancet Diabetes and Endocrinology, vol. 6, no. 4, pp. 299-309 . https://doi.org/10.1016/S2213-8587(18)30021-4 Rajendram, R, Taylor, P N, Wilson, V J, Harris, N, Morris, O C, Tomlinson, M, Yarrow, S, Garrott, H, Herbert, H M, Dick, A D, Cook, A, Gattamaneni, R, Jain, R, Olver, J, Hurel, S J, Bremner, F, Drummond, S R, Kemp, E, Ritchie, D M, Rumsey, N, Morris, D, Lane, C, Palaniappan, N, Li, C, Pell, J, Hills, R, Ezra, D G, Potts, M J, Jackson, S, Rose, G E, Plowman, N, Bunce, C, Uddin, J M, Lee, R W J & Dayan, C M 2018, ' Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED) : a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 6, no. 4, pp. 299-309 . https://doi.org/10.1016/S2213-8587(18)30021-4
Earl, H M, Hiller, L, Howard, H C, Dunn, J A, Young, J, Bowden, S J, McDermaid, M, Waterhouse, A K, Wilson, G, Agrawal, R, O'Reilly, S, Bowman, A, Ritchie, D M, Goodman, A, Hickish, T, McAdam, K, Cameron, D, Dodwell, D, Rea, D W, Caldas, C, Provenzano, E, Abraham, J E, Canney, P, Crown, J P, Kennedy, M J, Coleman, R, Leonard, R C, Carmichael, J A & Wardley, A M & Poole, C J 2017, ' Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial ', The Lancet Oncology . https://doi.org/10.1016/S1470-2045(17)30319-4